Verve Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 255
- Market Cap
- $467.1M
- Website
- http://www.vervetx.com
- Introduction
Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.
Phase 1b Study of VERVE-201 in Patients with Refractory Hyperlipidemia
Phase 1
Recruiting
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: VERVE-201
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Verve Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06451770
- Locations
- 🇬🇧
Clinical Study Center, London, United Kingdom
A Study of VERVE-102 in Patients with Familial Hypercholesterolemia or Premature Coronary Artery Disease
Phase 1
Recruiting
- Conditions
- Heterozygous Familial HypercholesterolemiaPremature Coronary Heart Disease
- Interventions
- Drug: VERVE-102
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Verve Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06164730
- Locations
- 🇬🇧
Clinical Study Center, Manchester, United Kingdom
Long-term Follow-up of Participants Dosed with an Investigational Gene Editing Therapy for Cardiovascular Disease
- Conditions
- HypercholesterolemiaAtherosclerotic Cardiovascular DiseaseHeterozygous Familial Hypercholesterolemia
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Verve Therapeutics, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT06112327
- Locations
- 🇬🇧
Clinical Study Center, London, United Kingdom
A Study of VERVE-101 in Patients with Familial Hypercholesterolemia and Cardiovascular Disease
Phase 1
Active, not recruiting
- Conditions
- Atherosclerotic Cardiovascular DiseaseHypercholesterolemiaHeterozygous Familial Hypercholesterolemia
- Interventions
- Drug: VERVE-101
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Verve Therapeutics, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT05398029
- Locations
- 🇬🇧
Clinical Study Center, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath